WGYRGFYC
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a KD of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer.
For research use only. We do not sell to patients.
- Formula: C51H62N12O11S
- Molecular Weight:1051.18
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
IC50 & Target
|
HER2 |
In Vitro
DOTA-WC8 (39-625 nM) binds to HER2 with nanomolar affinity (Kd=61.20 nM) in cell-free SPR assays[1].
[68Ga]Ga-DOTA-WGYRGFYC (37 KBq; 2 h) binds to HER2 in SKBR3 cells, with an IC50 of 51.89 nM[1].
Treatment with 10 μM Pyrotinib reduces the uptake of [68Ga]Ga-DOTA-WGYRGFYC (37 KBq; 15-120 min) by SKBR3 cells, indicating downregulation of HER2 expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
68Ga]Ga-DOTA-WC8 (3.7 MBq; i.v.; single dose) exhibits minimal accumulation in HER2-negative MDA-MB-231 tumors, confirming its HER2 specificity[1].
68Ga]Ga-DOTA-WC8 (i.v.; single dose) has favorable pharmacokinetics in normal mice with rapid distribution and clearance[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 4-5 weeks old)[1]
-
Dosage:3.7 MBq
-
Administration:i.v.; single dose
-
Result:Exhibited a two-compartment pharmacokinetic profile with a distribution half-life (T1/2α) of 2.898 min and an elimination half-life (T1/2β) of 23.477 min.
Rapidly absorbed by target tumor tissues, while the remaining radiotracer is efficiently cleared from the bloodstream, resulting in an optimal tumor/background ratio (TBR) at early time points postinjection.
Chemical Information
-
Molecular Weight 1051.18
-
Formula C51H62N12O11S
-
Sequence
Trp-Gly-Tyr-Arg-Gly-Phe-Tyr-Cys
-
Sequence Shortening
WGYRGFYC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)